emedicine.medscape.com

Fournier Gangrene: Practice Essentials, Background, Anatomy

  • ️Invalid Date

Practice Essentials

Fournier gangrene was first identified in 1883, when the French venereologist Jean Alfred Fournier described a series in which 5 previously healthy young men suffered from a rapidly progressive gangrene of the penis and scrotum without apparent cause. This condition, which came to be known as Fournier gangrene, is defined as a polymicrobial necrotizing fasciitis of the perineal, perianal, or genital areas (see the image below.)

Photomicrograph of Fournier gangrene (necrotizing

Photomicrograph of Fournier gangrene (necrotizing fasciitis), oil immersion at 1000X magnification. Note the acute inflammatory cells in the necrotic tissue. Bacteria are located in the haziness of their cytoplasm. Courtesy of Billie Fife, MD, and Thomas A. Santora, MD.

In contrast to Fournier's initial description, the disease is not limited to young people or to males, and a cause is now usually identified. [1, 2] Impaired immunity (eg, from diabetes) is known to increase susceptibility to Fournier gangrene. Trauma to the genitalia, which can cause a breach in the integrity of epithelial or urethral mucosa, is a frequently recognized mechanism by which bacteria are introduced, subsequently initiating the infectious process. [3, 4, 5] For more information, see the following Medscape articles:

Early, aggressive intervention is critical, as the condition is associated with a high mortality rate. Surgery is necessary for definitive diagnosis and excision of necrotic tissue. Along with debridement, surgical procedures may include complex closure, suprapubic tube placement, and fecal diversion. [6] Early administration of broad-spectrum antibiotics is indicated. Finally, any underlying comorbid conditions must ultimately be addressed. See Treatment and Medication.

eMedicine Logo

Background

In 1764, Baurienne originally described an idiopathic, rapidly progressive soft-tissue necrotizing process that led to gangrene of the male genitalia. However, the disease was named after Jean-Alfred Fournier, a Parisian venereologist, on the basis of a transcript from an 1883 clinical lecture in which Fournier presented a case of perineal gangrene in an otherwise healthy young man, adding this to a compiled series of 4 additional cases. [7] He differentiated these cases from perineal gangrene associated with diabetes, alcoholism, or known urogenital trauma, although these are currently recognized risk factors for the perineal gangrene now associated with his name.

This manuscript outlining Fournier’s initial series of fulminant perineal gangrene provides a fascinating insight into both the societal background and the practice of medicine at the time. In anecdotes, Fournier described recognized causes of perineal gangrene, including placement of a mistress’ ring around the phallus, ligation of the prepuce (used in an attempt to control enuresis or as an attempted birth control technique practiced by an adulterous man to avoid impregnating his married lover), placement of foreign bodies such as beans within the urethra, and excessive intercourse in diabetic and alcoholic persons. He calls upon physicians to be steadfast in obtaining confession from patients of “obscene practices.”

eMedicine Logo

Anatomy

The complex anatomy of the male external genitalia influences the initiation and progression of Fournier gangrene. This infectious process involves the superficial and deep fascial planes of the genitalia. As the microorganisms responsible for the infection multiply, infection spreads along the anatomical fascial planes, often sparing the deep muscular structures and, to variable degrees, the overlying skin, making the extent of involvement difficult to appreciate.

This phenomenon has implications for both initial debridement and subsequent reconstruction. Therefore, a working knowledge of the anatomy of the male lower urinary tract and external genitalia is critical for the clinician treating a patient with Fournier gangrene.

Skin and superficial fascia

Because Fournier gangrene is predominately an infectious process of the superficial and deep fascial planes, understanding the anatomic relationship of the skin and subcutaneous structures of the perineum and abdominal wall is important.

The skin cephalad to the inguinal ligament is backed by Camper fascia, which is a layer of fat-containing tissue of varying thickness and the superficial vessels to the skin that run through it. Scarpa fascia forms another distinct layer deep to Camper fascia. In the perineum, Scarpa fascia blends into Colles fascia (also known as the superficial perineal fascia), while it is continuous with Dartos fascia of the penis and scrotum (see the image below).

Fascial envelopment of the perineum (male). Note h

Fascial envelopment of the perineum (male). Note how Colles fascia completely envelops the scrotum and penis. Colles fascia is in continuity cephalad to the level of the clavicles. In the inguinal region, this fascial layer is known as Scarpa fascia. Familiarity with this fascial anatomy, along with recognition that necrotizing fasciitis tends to spread along fascial planes, makes it easy to understand how a process that starts in the perineum can spread to the abdominal wall, the flank, and even the chest wall.

Several important anatomic relationships should be considered. A potential space between the Scarpa fascia and the deep fascia of the anterior wall (external abdominal oblique) allows for the extension of a perineal infection into the anterior abdominal wall. Superiorly, Scarpa and Camper fascia coalesce and attach to the clavicles, ultimately limiting the cephalad extension of an infection that may have originated in the perineum.

Colles fascia is attached to the pubic arch and the base of the perineal membrane, and is continuous with the superficial Dartos fascia of the scrotal wall. The perineal membrane is also known as the inferior fascia of the urogenital diaphragm and, together with Colles fascia, defines the superficial perineal space.

This space contains the membranous urethra, bulbar urethra, and bulbourethral glands. In addition, this space is adjacent to the anterior anal wall and ischiorectal fossae. Infectious disease of the male urethra, bulbourethral glands, perineal structures, or rectum can drain into the superficial perineal space and can extend into the scrotum or into the anterior abdominal wall up to the level of the clavicles.

Vascular supply to the skin of the lower abdomen and genitalia

Branches from the inferior epigastric and deep circumflex iliac arteries supply the lower aspect of the anterior abdominal wall. Branches of the external and internal pudendal arteries supply the scrotal wall. With the exception of the internal pudendal artery, each of these vessels travels within Camper fascia and can therefore become thrombosed in the progression of Fournier gangrene.

Thrombosis jeopardizes the viability of the skin of the anterior scrotum and perineum. Since the internal pudendal artery is not contained within Camper fascia, it is less susceptible to thrombosis; therefore, its vascular territory—the posterior aspect of the scrotal wall—remains viable and can be used in the reconstruction following resolution of the infection.

Penis and scrotum

The contents of the scrotum, namely the testicles, epididymides, and cord structures, are invested by several fascial layers distinct from the Dartos fascia of the scrotal wall. Again, several important anatomic relationships should be considered.

The most superficial layer of the testis and cord is the external spermatic fascia, which is continuous with the external aponeurosis of the superficial inguinal ring (external abdominal oblique). The next deeper layer is the internal spermatic fascia, which is continuous with the transversalis fascia. A deep fascia termed Buck fascia covers the erectile bodies of the penis, the corpora cavernosa, and the anterior urethra. Buck fascia fuses to the dense tunica albuginea of the corpora cavernosa, deep in the pelvis.

The fascial layers described in this section do not become involved with an infection of the superficial perineal space and can limit the depth of tissue destruction in a necrotizing infection of the genitalia. The corpora cavernosa, urethra, testes, and cord structures are usually spared in Fournier gangrene, while the superficial and deep fascia and the skin are destroyed.

eMedicine Logo

Pathophysiology

Localized infection adjacent to a portal of entry is the inciting event in the development of Fournier gangrene. Ultimately, an obliterative endarteritis develops, and the ensuing cutaneous and subcutaneous vascular necrosis leads to localized ischemia and further bacterial proliferation. Rates of fascial destruction as high as 2-3 cm/h have been described.

Infection of superficial perineal fascia (Colles fascia) may spread to the penis and scrotum via Buck and Dartos fascia, or to the anterior abdominal wall via Scarpa fascia, or vice versa. Colles fascia is attached to the perineal body and urogenital diaphragm posteriorly and to the pubic rami laterally, thus limiting progression in these directions. Testicular involvement is rare, as the testicular arteries originate directly from the aorta and thus have a blood supply separate from the affected region. Far-advanced or fulminant Fournier gangrene can spread from the fascial envelopment of the genitalia throughout the perineum, along the torso, and, occasionally, into the thighs.

The following are pathognomonic findings of Fournier gangrene upon pathologic evaluation of involved tissue:

  • Necrosis of the superficial and deep fascial planes<

  • Fibrinoid coagulation of the nutrient arterioles

  • Polymorphonuclear cell infiltration

  • Microorganisms identified within the involved tissues

Infection represents an imbalance between (1) host immunity, which is frequently compromised by one or more comorbid systemic processes, and (2) the virulence of the causative microorganisms. The etiologic factors allow the portal for entry of the microorganism into the perineum; the compromised immunity provides a favorable environment to initiate the infection; and the virulence of the microorganism promotes the rapid spread of the disease. See the image below.

Necrotizing infection results when the pathogen is

Necrotizing infection results when the pathogen is extremely virulent or, most commonly, when a combination of microorganisms act synergistically in a susceptible immunocompromised host.

Microorganism virulence results from the production of toxins or enzymes that create an environment conducive to rapid microbial multiplication. [8] Although Meleney in 1924 attributed the necrotizing infections to streptococcal species only, [9] subsequent clinical series have emphasized the multiorganism nature of most cases of necrotizing infection, including Fournier gangrene. [10, 11, 12, 13, 14]

Presently, recovering only streptococcal species is unusual. [15] Rather, streptococcal organisms are cultured along with as many as 5 other organisms.

The following are common causative microorganisms:

  • Streptococcal species

  • Staphylococcal species

  • Enterobacteriaceae

  • Anaerobic organisms

  • Fungi

Most authorities believe that polymicrobial involvement is necessary to create the synergy of enzyme production that promotes rapid multiplication and spread of Fournier gangrene. [8] For example, one microorganism might produce the enzymes necessary to cause coagulation of the nutrient vessels. Thrombosis of these nutrient vessels reduces local blood supply; thus, tissue oxygen tension falls.

The resultant tissue hypoxia allows for the growth of facultative anaerobes and microaerophilic organisms. These latter microorganisms, in turn, may produce enzymes (eg, lecithinase, collagenase), which lead to digestion of fascial barriers, thus fueling the rapid extension of the infection.

Fascial necrosis and digestion are hallmarks of this disease process; this is important to appreciate because it provides the surgeon with a clinical marker of the extent of tissue involvement. Specifically, if the fascial plane can be separated easily from the surrounding tissue by blunt dissection, it is quite likely to be involved with the ischemic-infectious process; therefore, any such dissected tissue should be excised.

eMedicine Logo

Etiology

Although originally described as idiopathic gangrene of the genitalia, Fournier gangrene has an identifiable cause in 75-95% of cases. [16] The necrotizing process commonly originates from an infection in the anorectum, the urogenital tract, or the skin of the genitalia. [17]

Anorectal causes of Fournier gangrene include perianal, perirectal, and ischiorectal abscesses; anal fissures; anal fistula; and colonic perforations. These may be a consequence of colorectal injury or a complication of colorectal malignancy, [18, 19] inflammatory bowel disease, [20] colonic diverticulitis, or appendicitis.

A case of Fournier gangrene was reported in a patient with COVID-19 following prolonged and repeated ventilation in prone position. [21]

Urogenital tract causes include the following:

  • Infection in the bulbourethral glands

  • Urethral injury

  • Iatrogenic injury secondary to urethral stricture manipulation

  • Epididymitis

  • Orchitis

  • Lower urinary tract infection (eg, in patients with long-term indwelling urethral catheters)

Dermatologic causes include hidradenitis suppurativa, ulceration due to scrotal pressure, and trauma. Inability to practice adequate perineal hygiene, such as in paraplegic patients, results in increased risk.

Accidental, intentional, or surgical trauma [22] and the presence of foreign bodies may also lead to the disease. The following have been reported in the literature as precipitating factors:

  • Blunt thoracic trauma

  • Superficial soft-tissue injuries

  • Genital piercings

  • Penile self-injection with cocaine [23]

  • Urethral instrumentation

  • Prosthetic penile implants

  • Intramuscular injections

  • Steroid enemas (used for the treatment of radiation proctitis)

  • Rectal foreign body [24]

In women, septic abortions, vulvar or Bartholin gland abscesses, hysterectomy, and episiotomy are documented sources. A comprehensive literature review of 134 women with Fournier gangrene reported that perineal abscess was the most common etiology (n=41, 35%). [2] In men, anal intercourse may increase risk of perineal infection, either from blunt trauma to the area or by spread of rectally carried microbes.

In children, the following have led to the disease:

  • Circumcision

  • Phimosis

  • Strangulated inguinal hernia

  • Omphalitis

  • Insect bites

  • Trauma

  • Urethral instrumentation

  • Prematurity [25]

  • Perirectal abscesses

  • Systemic infections

  • Diaper rash [25]

  • Secondary immunodeficiency

A case report by Numoto et al describes Fournier gangrene that developed after surgical repair of a strangulated inguinal hernia in a 2-month-old boy. The boy was receiving adrenocorticotropic hormone (ACTH) therapy for infantile spasms, and the authors suggest that immune suppression from the ACTH may have contributed to the development of Fournier gangrene. [26]

Pathogens

Wound cultures from patients with Fournier gangrene reveal that it is a polymicrobial infection with an average of 4 isolates per case. Escherichia coli is the predominant aerobe, and Bacteroides is the predominant anaerobe.

Other common microflora include the following:

  • Proteus

  • Staphylococcus

  • Enterococcus

  • Streptococcus (aerobic and anaerobic)

  • Pseudomonas

  • Klebsiella

  • Clostridium [27]

Rarely, Candida albicans has been reported as the pathogen in cases of Fournier gangrene. [28, 29, 30]

Predisposition to disease

Any condition that depresses cellular immunity may predispose a patient to the development of Fournier gangrene. Examples include the following:

  • Diabetes mellitus (present in as many as 60% of cases) [31, 27]

  • Morbid obesity

  • Alcoholism

  • Cirrhosis

  • Extremes of age

  • Vascular disease of the pelvis

  • Malignancy (eg, acute leukemia) [32, 33]

  • Systemic lupus erythematosus [34]

  • Crohn disease

  • HIV infection [35] ref34}

  • Malnutrition

  • Iatrogenic immunosuppression (eg, from long-term corticosteroid therapy or chemotherapy [36] )

The US Food and Drug Administration (FDA) has noted an increased risk for Fournier gangrene in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors were first approved in 2013, and by 2019, 55 cases of Fournier gangrene had been reported in patients receiving these agents. By comparison, only 19 cases of Fournier gangrene have been reported over 35 years in patients taking other diabetes drugs. [37]

Details of Fournier gangrene cases associated with SGLT2 inhibitors included the following [37] :

  • Patients ranged in age from 33 to 87 years; 39 were men, 16 were women.

  • Onset of Fournier gangrene after initiation of SGLT2 inhibitors ranged from 5 days to 49 months.

  • Complications included diabetic ketoacidosis, sepsis, and kidney injury.

  • Eight patients underwent fecal diversion surgery, two patients required amputation of a lower extremity due to  necrotizing fasciitis, and three patients died.

eMedicine Logo

Epidemiology

Fournier gangrene is relatively uncommon, but the exact incidence of the disease is unknown. In a review of Fournier gangrene in 1992, Paty et al calculated that approximately 500 cases of the infection had been reported in the literature since Fournier’s 1883 report, yielding a rate of 1 case in 7500 persons. [38] A retrospective case review revealed 1726 cases documented in the literature from 1950-1999, with an average of 97 cases per year reported from 1989-1998. [39] A review of National Inpatient Sample data from 2004-2012 identified a total of 9249 patients with Fournier gangrene. [6]

A review using the US State Inpatient Database in 2009 estimated that among 25.8 million hospital admissions from 2001 and 2004, Fournier gangrene constituted only 0.02% of hospital admissions. In this same database, 66% of the hospitals reported no patients with Fournier gangrene, and among high volume centers, the admission frequency was only 1 patient every few months. [40]

The frequency of Fournier gangrene has not likely changed appreciably. Rather, the apparent increase in the number of cases in the literature most likely results from increased reporting.

No seasonal variation occurs. Fournier gangrene is not indigenous to any region of the world, although the largest clinical series originate from the African continent. [41]

Sex- and age-related differences in incidence

The typical patient with Fournier gangrene is an elderly man in his sixth or seventh decade of life with comorbid diseases. The male-to-female ratio is approximately 10:1. The lower incidence in females may reflect better drainage of the perineal region through vaginal secretions. [2]

Men who have sex with men may be at higher risk, especially for infections caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA). [42]

Most reported cases occur in patients aged 30-60 years. A literature review found only 56 pediatric cases, with 66% of those in infants younger than 3 months.

eMedicine Logo

Prognosis

Large scrotal, perineal, penile, and abdominal wall skin defects may require reconstructive procedures; however, the prognosis for patients following reconstruction for Fournier gangrene is usually good. The scrotum has a remarkable ability to heal and regenerate once the infection and necrosis have subsided. However, approximately 50% of men with penile involvement have pain with erection, often related to genital scarring. Consultation with a psychiatrist may help some patients deal with the emotional stress of an altered body image.

If extensive soft tissue is lost, lymphatic drainage may be impaired; thus, dependent edema and cellulitis may result. Use of external support may be beneficial to minimize this postoperative problem.

To date, the majority of studies of Fournier gangrene have been retrospective reviews. [43, 44] Therefore, the utility of drawing reliable prognostic information from these studies is very limited.

In 1995, Laor and colleagues introduced the Fournier Gangrene Severity Index (FGSI). [45] The FGSI is based on deviation from reference ranges of the following clinical parameters:

  • Temperature

  • Heart rate

  • Respiratory rate

  • White blood cell count (WBC)

  • Hematocrit

  • Serum sodium

  • Serum potassium

  • Serum creatinine

  • Serum bicarbonate

Each parameter is assigned a score between 0 and 4, with the higher values indicating greater deviation from normal. The FGSI represents the sum of all the parameters’ values.

Laor and colleagues determined that an FGSI greater than 9 correlated with increased mortality. [45] The FGSI has been validated in several retrospective studies. [46, 47, 48] In a retrospective review of 20 patients with Fournier gangrene, the average FGSI was 9 overall and 14 for fatal cases. An increased FGSI was predictive of having an increased mortality rate or hospital stay longer than the median (>25 days) (P=0.0194). [49]

In 2010, Yilmazlar and colleagues updated the FGSI (UFGSI), adding two additional parameters—age and extent of disease—to further refine the prognostic utility of the FGSI. [50]

These two groups concluded that the mortality risk in general may be directly proportional to the age of the patient and the extent of disease burden and systemic toxicity upon admission. Factors associated with an improved prognosis included the following [50, 51, 52] :

  • Age younger than 60 years

  • Localized clinical disease

  • Absence of systemic toxicity (eg, low FGSI)

  • Sterile blood cultures

Most recently, Roghmann et al queried whether these increasingly complex scoring systems actually outperformed two existing and less burdensome morbidity scoring systems, the age-adjusted Charlson Comorbidity Index (ACCI) and the surgical APGAR score (sAPGAR). [53] They assessed this retrospectively then prospectively with a 30-day follow-up. They noted that ACCI and sAPGAR performed as well as the FGSI and UFGSI and were easier to calculate at the bedside. Again, increasing age and medical comorbidities were associated with increased risk of death. [53]

Bozkurt et al reached a similar conclusion in their comparison of the FGSI; the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC), which is based on the WBC, hemoglobin, serum sodium, glucose, serum creatinine, and C-reactive protein levels; and the neutrophil/lymphocyte ratio (NLR)—a marker for inflammation that has been studied as a prognostic indicator in a variety of conditions, primarily cancer and heart disease. In their retrospective cohort studies, higher scores in all three scoring systems (FGSI ≥4, LRINEC ≥6, NLR ≥10) identified patients with a worse prognosis, including need for mechanical ventilation requirement and mortality. However, the NLR had the advantages of speed, simplicity, and low cost. [54]  

In a retrospective case series that included 19 patients with a median age of 70 years, Morais et al reported that the percentage of body surface area (BSA) affected proved to be a useful prognostic factor. Combining the LRINEC model with a BSA >3.25% led to a major improvement in the accuracy of the scores. [51]

In a retrospective review of 54 patients with a mean age of 49.3 years and a mean body mass index (BMI) of 28.6 kg/m2, patients on average were hospitalized for 37.5 days, with a mean intensive care unit stay of 8.3 days. Three patients (5.6%) died during their hospital stay, and 33 (61%) required reconstructive surgery. Multivariate logistic modeling showed that BMI (P=0.001) and alkaline phosphatase (P< 0.001) correlated with decreasing length of stay, while age at admission was not significantly correlated (P=0.369). [55]

This study also developed a novel scoring system, the Combined Urology and Plastics Index (CUPI), designed to predict length of stay in Fournier gangrene patients. CUPI parameters include the following:

  • Age at admission

  • Hematocrit

  • Plasma CO2 (serum bicarbonate)

  • Blood urea nitrogen

  • Serum calcium

  • Alkaline phosphatase

  • Albumin

  • International normalized ratio (INR)

  • Lactate

  • Total bilirubin

The CUPI scoring system has a minimum score of 0 and a maximum score of 15. Patients with CUPI scores ≤5 had an average length of stay of 25 days (standard deviation [SD], 15.6), while those with CUPI scores >5 had an average length of stay of 71 days (SD 49.8). [55]

Interestingly, obesity is independently associated with reduced in-hospital mortality in patients with severe soft tissue infections (SSTIs) regardless of the obesity classification, according to a review of 2868 patients with SSTIs, which found that obese patients were less likely to die in hospital than nonobese patients (odds ratio = 0.42, 95% confidence index, 0.25 to 0.7, P=0.001). [56]

Surprisingly, diabetes and HIV infection are not associated with higher mortality. In some studies, Fournier gangrene that originates from anorectal diseases carries a worse prognosis than cases caused by other factors.

The reported mortality rates for Fournier gangrene have varied widely, ranging as high as 75%. Joseph Jones, a Confederate army surgeon, was the first person to describe the mortality of Fournier gangrene in a large population of men. He reported a mortality rate of 46% in 2642 affected Confederate soldiers during the Civil War. [57]

Using National Surgical Quality Improvement Program data from 2005 to 2009, Kim et al determined that the overall 30-day mortality rate for Fournier gangrene and necrotizing fasciitis of the genitalia was 10.1% (64 of 636 patients)—a rate about half that of historically published estimates, but similar to that in recent studies. [58] A review of 25.8 million hospital admission in 2001 and 2004, using the US State Inpatient Database, estimated that Fournier gangrene constituted only 0.02% of hospital admissions and carred a 7.5% case fatality rate. [40] A review by Furr et al of National Inpatient Sample data on Fournier gangrene from 2004 to 2012 found that inpatient mortality was 4.7%. [6]

Factors associated with high mortality include an anorectal source, advanced age, extensive disease (involving abdominal wall or thighs), shock or sepsis at presentation, renal failure, and hepatic dysfunction. [59]  In a Turkish study of 50 patients, Acinetobacter baumannii and Klebsiella pneumoniae were significantly more common in patients who required mechanical ventilation, but A baumannii was the only microorganism associated with an increased mortality rate. [60]

Death usually results from systemic illness, such as sepsis (usually gram negative), coagulopathy, acute kidney injury, diabetic ketoacidosis, or multiple organ failure. Fatal tetanus associated with Fournier gangrene has been reported in the literature.

eMedicine Logo

  1. Pernetti R, Palmieri F, Sagrini E, Negri M, Morisi C, Carbone A, et al. Fournier's gangrene: Clinical case and review of the literature. Arch Ital Urol Androl. 2016 Oct 5. 88 (3):237-238. [QxMD MEDLINE Link].

  2. Khalid A, Devakumar S, Huespe I, Kashyap R, Chisti I. A Comprehensive Literature Review of Fournier's Gangrene in Females. Cureus. 2023 May. 15 (5):e38953. [QxMD MEDLINE Link]. [Full Text].

  3. Ekelius L, Björkman H, Kalin M, Fohlman J. Fournier's gangrene after genital piercing. Scand J Infect Dis. 2004. 36(8):610-2. [QxMD MEDLINE Link].

  4. Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am. 1994 Dec. 74 (6):1339-52. [QxMD MEDLINE Link].

  5. Stephens BJ, Lathrop JC, Rice WT, Gruenberg JC. Fournier's gangrene: historic (1764-1978) versus contemporary (1979-1988) differences in etiology and clinical importance. Am Surg. 1993 Mar. 59 (3):149-54. [QxMD MEDLINE Link].

  6. Furr J, Watts T, Street R, Cross B, Slobodov G, Patel S. Contemporary Trends in the Inpatient Management of Fournier's Gangrene: Predictors of Length of Stay and Mortality Based on Population-Based Sample. Urology. 2016 Sep 27. 382(1):15-8. [QxMD MEDLINE Link].

  7. Corman JM. Classic articles in colonic and rectal surgery. Dis Colon Rectum. 1988. 31:984-8.

  8. Mergenhagen SE, Thonard JC, Scherp HW. Studies on synergistic infections. I. Experimental infections with anaerobic streptococci. J Infect Dis. 1958 Jul-Aug. 103(1):33-44. [QxMD MEDLINE Link].

  9. Meleney FL. Hemolytic Streptococcus gangrene. Arch Surg. 1924. 9:317-21.

  10. Moses AE. Necrotizing fasciitis: flesh-eating microbes. Isr J Med Sci. 1996 Sep. 32(9):781-4. [QxMD MEDLINE Link].

  11. Benizri E, Fabiani P, Migliori G, et al. Gangrene of the perineum. Urology. 1996 Jun. 47(6):935-9. [QxMD MEDLINE Link].

  12. Benchekroun A, Lachkar A, Bjijou Y, et al. [Gangrene of the external genital organs. Apropos of 55 cases]. J Urol (Paris). 1997. 103(1-2):27-31. [QxMD MEDLINE Link].

  13. Ben-Aharon U, Borenstein A, Eisenkraft S, et al. Extensive necrotizing soft tissue infection of the perineum. Isr J Med Sci. 1996 Sep. 32(9):745-9. [QxMD MEDLINE Link].

  14. Basoglu M, Gül O, Yildirgan I, Balik AA, Ozbey I, Oren D. Fournier's gangrene: review of fifteen cases. Am Surg. 1997 Nov. 63(11):1019-21. [QxMD MEDLINE Link].

  15. Goyette M. Group A streptococcal necrotizing fasciitis Fournier's gangrene--Quebec. Can Commun Dis Rep. 1997 Jul 1. 23(13):101-3. [QxMD MEDLINE Link].

  16. Smith GL, Bunker CB, Dinneen MD. Fournier's gangrene. Br J Urol. 1998 Mar. 81(3):347-55. [QxMD MEDLINE Link].

  17. Clayton MD, Fowler JE Jr, Sharifi R, Pearl RK. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet. 1990 Jan. 170(1):49-55. [QxMD MEDLINE Link].

  18. Ossibi PE, Souiki T, Ibn Majdoub K, Toughrai I, Laalim SA, Mazaz K, et al. Fournier gangrene: rare complication of rectal cancer. Pan Afr Med J. 2015. 20:288. [QxMD MEDLINE Link]. [Full Text].

  19. Bruketa T, Majerovic M, Augustin G. Rectal cancer and Fournier's gangrene - current knowledge and therapeutic options. World J Gastroenterol. 2015 Aug 14. 21 (30):9002-20. [QxMD MEDLINE Link]. [Full Text].

  20. Brings HA, Matthews R, Brinkman J, Rotolo J. Crohn's disease presenting with Fournier's gangrene and enterovesical fistula. Am Surg. 1997 May. 63(5):401-5. [QxMD MEDLINE Link].

  21. Kappel C, Piticaru J, Jones G, Goucher G, Cheon P, Fischer M, et al. A case of possible Fournier's gangrene associated with proning in COVID-19 ARDS. Can J Anaesth. 2020 Nov. 67 (11):1697-1698. [QxMD MEDLINE Link]. [Full Text].

  22. [Guideline] Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014 Jul 15. 59 (2):147-59. [QxMD MEDLINE Link]. [Full Text].

  23. Mouraviev VB, Pautler SE, Hayman WP. Fournier's gangrene following penile self-injection with cocaine. Scand J Urol Nephrol. 2002. 36(4):317-8. [QxMD MEDLINE Link].

  24. Abate G, Shirin M, Kandanati V. Fournier gangrene from a thirty-two-centimeter rectosigmoid foreign body. J Emerg Med. 2013 Feb. 44(2):e247-9. [QxMD MEDLINE Link].

  25. Ekingen G, Isken T, Agir H, Oncel S, Günlemez A. Fournier's gangrene in childhood: a report of 3 infant patients. J Pediatr Surg. 2008 Dec. 43 (12):e39-42. [QxMD MEDLINE Link].

  26. Numoto S, Kurahashi H, Azuma Y, Numaguchi A, Nakahara K, Tainaka T, et al. Fournier's gangrene during ACTH therapy. Brain Dev. 2017 May. 39 (5):435-438. [QxMD MEDLINE Link].

  27. Huang CS. Fournier's Gangrene. N Engl J Med. 2017 Mar 23. 376 (12):1158. [QxMD MEDLINE Link]. [Full Text].

  28. Perkins TA, Bieniek JM, Sumfest JM. Solitary Candida albicans Infection Causing Fournier Gangrene and Review of Fungal Etiologies. Rev Urol. 2014. 16 (2):95-8. [QxMD MEDLINE Link].

  29. Jaworski R, Irga-Jaworska N, Naumiuk Ł, Chojnicki M, Haponiuk I. Fournier Gangrene Caused by Candida albicans in an Infant After Cardiac Surgery. Mycopathologia. 2016 Nov 2. [QxMD MEDLINE Link].

  30. Jaworski R, Irga-Jaworska N, Naumiuk Ł, Chojnicki M, Haponiuk I. Fournier Gangrene Caused by Candida albicans in an Infant After Cardiac Surgery. Mycopathologia. 2017 Apr. 182 (3-4):409-412. [QxMD MEDLINE Link]. [Full Text].

  31. Rajbhandari SM, Wilson RM. Unusual infections in diabetes. Diabetes Res Clin Pract. 1998 Feb. 39(2):123-8. [QxMD MEDLINE Link].

  32. Faber HJ, Girbes AR, Daenen S. Fournier's gangrene as first presentation of promyelocytic leukemia. Leuk Res. 1998 May. 22(5):473-6. [QxMD MEDLINE Link].

  33. Martinelli G, Alessandrino EP, Bernasconi P, et al. Fournier's gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation. Bone Marrow Transplant. 1998 Nov. 22(10):1023-6. [QxMD MEDLINE Link].

  34. Kohagura K, Sesoko S, Tozawa M, et al. [A female case of Fournier's gangrene in a patient with lupus nephritis]. Nippon Jinzo Gakkai Shi. 1998 Jul. 40(5):354-8. [QxMD MEDLINE Link].

  35. Roca B, Cuñat E, Simón E. HIV infection presenting with Fournier's gangrene. Neth J Med. 1998 Oct. 53(4):168-71. [QxMD MEDLINE Link].

  36. Gonzaga-López A, Muñoz-Rodriguez J, Ruiz-Casado A. Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report. Ann R Coll Surg Engl. 2017 Nov. 99 (8):e225-e226. [QxMD MEDLINE Link].

  37. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019 May 7. [QxMD MEDLINE Link].

  38. Paty R, Smith AD. Gangrene and Fournier's gangrene. Urol Clin North Am. 1992 Feb. 19(1):149-62. [QxMD MEDLINE Link].

  39. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000 Jun. 87(6):718-28. [QxMD MEDLINE Link].

  40. Sorensen MD, Krieger JN. Fournier's Gangrene: Epidemiology and Outcomes in the General US Population. Urol Int. 2016. 97 (3):249-259. [QxMD MEDLINE Link]. [Full Text].

  41. Ngugi P, Magoha G, Nyaga P. Fournier's ganrene in the HIV era. Afr Health Sci. 2014 Dec. 14 (4):1063-8. [QxMD MEDLINE Link]. [Full Text].

  42. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008 Feb 19. 148(4):249-57. [QxMD MEDLINE Link].

  43. Corman JM, Moody JA, Aronson WJ. Fournier's gangrene in a modern surgical setting: improved survival with aggressive management. BJU Int. 1999 Jul. 84(1):85-8. [QxMD MEDLINE Link].

  44. Chen CS, Liu KL, Chen HW, Chou CC, Chuang CK, Chu SH. Prognostic factors and strategy of treatment in Fournier's gangrene: a 12-year retrospective study. Changgeng Yi Xue Za Zhi. 1999 Mar. 22(1):31-6. [QxMD MEDLINE Link].

  45. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. J Urol. 1995 Jul. 154(1):89-92. [QxMD MEDLINE Link].

  46. Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ. Validation of the Fournier's gangrene severity index in a large contemporary series. J Urol. 2008 Sep. 180(3):944-8. [QxMD MEDLINE Link].

  47. Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology. 2004 Aug. 64(2):218-22. [QxMD MEDLINE Link].

  48. Ulug M, Gedik E, Girgin S, Celen MK, Ayaz C. The evaluation of microbiology and Fournier's gangrene severity index in 27 patients. Int J Infect Dis. 2009 Nov. 13(6):e424-30. [QxMD MEDLINE Link].

  49. Ferretti M, Saji AA, Phillips J. Fournier's Gangrene: A Review and Outcome Comparison from 2009 to 2016. Adv Wound Care (New Rochelle). 2017 Sep 1. 6 (9):289-295. [QxMD MEDLINE Link]. [Full Text].

  50. Yilmazlar T, Ozturk E, Ozguc H, Ercan I, Vuruskan H, Oktay B. Fournier's gangrene: an analysis of 80 patients and a novel scoring system. Tech Coloproctol. 2010 Sep. 14(3):217-23. [QxMD MEDLINE Link].

  51. Morais H, Neves J, Maciel Ribeiro H, Ferreira M, Guimarães N, Azenha N, et al. Case series of Fournier's gangrene: Affected body surface area - The underestimated prognostic factor. Ann Med Surg (Lond). 2017 Apr. 16:19-22. [QxMD MEDLINE Link]. [Full Text].

  52. Norton KS, Johnson LW, Perry T, et al. Management of Fournier's gangrene: an eleven year retrospective analysis of early recognition, diagnosis, and treatment. Am Surg. 2002 Aug. 68(8):709-13. [QxMD MEDLINE Link].

  53. Roghmann F, von Bodman C, Löppenberg B, Hinkel A, Palisaar J, Noldus J. Is there a need for the Fournier's gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier's gangrene. BJU Int. 2012 Nov. 110(9):1359-65. [QxMD MEDLINE Link].

  54. Bozkurt O, Sen V, Demir O, Esen A. Evaluation of the utility of different scoring systems (FGSI, LRINEC and NLR) in the management of Fournier's gangrene. Int Urol Nephrol. 2015 Feb. 47 (2):243-8. [QxMD MEDLINE Link].

  55. Ghodoussipour SB, Gould D, Lifton J, Badash I, Krug A, Miranda G, et al. Surviving Fournier's gangrene: Multivariable analysis and a novel scoring system to predict length of stay. J Plast Reconstr Aesthet Surg. 2017 Dec 14. [QxMD MEDLINE Link].

  56. Rios-Diaz AJ, Lin E, Williams K, Jiang W, Patel V, Shimizu N, et al. The obesity paradox in patients with severe soft tissue infections. Am J Surg. 2017 Sep. 214 (3):385-389. [QxMD MEDLINE Link].

  57. Jones J, US Sanitary Commission. Investigation upon the nature, causes and treatment of hospital gangrene as it prevailed in the Confederate Armies 1861-1865. Surgical Memoirs of the War of the Rebellion. New York, NY: Hurd and Houghton; 1871. 142-580.

  58. Kim SY, Dupree JM, Le BV, Kim DY, Zhao LC, Kundu SD. A contemporary analysis of Fournier gangrene using the National Surgical Quality Improvement Program. Urology. 2015 May. 85 (5):1052-6. [QxMD MEDLINE Link].

  59. Czymek R, Hildebrand P, Kleemann M, et al. New insights into the epidemiology and etiology of Fournier's gangrene: a review of 33 patients. Infection. 2009 Aug. 37(4):306-12. [QxMD MEDLINE Link].

  60. Yilmazlar T, Gulcu B, Isik O, Ozturk E. Microbiological aspects of Fournier's gangrene. Int J Surg. 2017 Apr. 40:135-138. [QxMD MEDLINE Link].

  61. Fan CM, Whitman GJ, Chew FS. Radiologic-Pathologic Conferences of the Massachusetts General Hospital. Necrotizing fasciitis of the scrotum (Fournier's gangrene). AJR Am J Roentgenol. 1996 May. 166(5):1164. [QxMD MEDLINE Link].

  62. Rajan DK, Scharer KA. Radiology of Fournier's gangrene. AJR Am J Roentgenol. 1998 Jan. 170(1):163-8. [QxMD MEDLINE Link].

  63. Sherman J, Solliday M, Paraiso E, Becker J, Mydlo JH. Early CT findings of Fournier's gangrene in a healthy male. Clin Imaging. 1998 Nov-Dec. 22(6):425-7. [QxMD MEDLINE Link].

  64. Wysoki MG, Santora TA, Shah RM, Friedman AC. Necrotizing fasciitis: CT characteristics. Radiology. 1997 Jun. 203(3):859-63. [QxMD MEDLINE Link].

  65. Kane CJ, Nash P, McAninch JW. Ultrasonographic appearance of necrotizing gangrene: aid in early diagnosis. Urology. 1996 Jul. 48(1):142-4. [QxMD MEDLINE Link].

  66. Auerbach J, Bornstein K, Ramzy M, Cabrera J, Montrief T, Long B. Fournier Gangrene in the Emergency Department: Diagnostic Dilemmas, Treatments and Current Perspectives. Open Access Emerg Med. 2020. 12:353-364. [QxMD MEDLINE Link]. [Full Text].

  67. Sugihara T, Yasunaga H, Horiguchi H, Fujimura T, Ohe K, Matsuda S, et al. Impact of surgical intervention timing on the case fatality rate for Fournier's gangrene: an analysis of 379 cases. BJU Int. 2012 Dec. 110(11 Pt C):E1096-100. [QxMD MEDLINE Link].

  68. El-Shazly M, Aziz M, Aboutaleb H, Salem S, El-Sherif E, Selim M, et al. Management of equivocal (early) Fournier's gangrene. Ther Adv Urol. 2016 Oct. 8 (5):297-301. [QxMD MEDLINE Link]. [Full Text].

  69. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988 Jul. 158(1):23-8. [QxMD MEDLINE Link].

  70. Cawley MJ, Briggs M, Haith LR Jr, et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy. 1999 Sep. 19(9):1094-8. [QxMD MEDLINE Link].

  71. Karian LS, Chung SY, Lee ES. Reconstruction of Defects After Fournier Gangrene: A Systematic Review. Eplasty. 2015. 15:e18. [QxMD MEDLINE Link]. [Full Text].

  72. Konofaos P, Hickerson WL. A Technique for Improving Cosmesis After Primary Scrotum Reconstruction With Skin Grafts. Ann Plast Surg. 2015 Aug. 75 (2):205-7. [QxMD MEDLINE Link].

  73. Korhonen K, Hirn M, Niinikoski J. Hyperbaric oxygen in the treatment of Fournier's gangrene. Eur J Surg. 1998 Apr. 164(4):251-5. [QxMD MEDLINE Link].

  74. Pizzorno R, Bonini F, Donelli A, Stubinski R, Medica M, Carmignani G. Hyperbaric oxygen therapy in the treatment of Fournier's disease in 11 male patients. J Urol. 1997 Sep. 158(3 Pt 1):837-40. [QxMD MEDLINE Link].

  75. Hollabaugh RS Jr, Dmochowski RR, Hickerson WL, Cox CE. Fournier's gangrene: therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg. 1998 Jan. 101(1):94-100. [QxMD MEDLINE Link].

  76. Mladenov A, Diehl K, Müller O, von Heymann C, Kopp S, Peitsch WK. Outcome of necrotizing fasciitis and Fournier's gangrene with and without hyperbaric oxygen therapy: a retrospective analysis over 10 years. World J Emerg Surg. 2022 Aug 5. 17 (1):43. [QxMD MEDLINE Link]. [Full Text].

  77. Mindrup SR, Kealey GP, Fallon B. Hyperbaric oxygen for the treatment of fournier's gangrene. J Urol. 2005 Jun. 173(6):1975-7. [QxMD MEDLINE Link].

  78. Nomikos IN. Necrotizing perineal infections (Fournier's disease): old remedies for an old disease. Int J Colorectal Dis. 1998. 13(1):48-51. [QxMD MEDLINE Link].

  79. Asci R, Sarikaya S, Büyükalpelli R, Yilmaz AF, Yildiz S. Fournier's gangrene: risk assessment and enzymatic debridement with lyophilized collagenase application. Eur Urol. 1998. 34(5):411-8. [QxMD MEDLINE Link].

  80. Hersant B, SidAhmed-Mezi M, Bosc R, Meningaud JP. Autologous Platelet-Rich Plasma/Thrombin Gel Combined with Split-Thickness Skin Graft to Manage Postinfectious Skin Defects: A Randomized Controlled Study. Adv Skin Wound Care. 2017 Nov. 30 (11):502-508. [QxMD MEDLINE Link].

  81. Ingraham AM, Jung HS, Liepert AE, Warner-Hillard C, Greenberg CC, Scarborough JE. Effect of transfer status on outcomes for necrotizing soft tissue infections. J Surg Res. 2017 Dec. 220:372-378. [QxMD MEDLINE Link].

Author

Vernon M Pais, Jr, MD Associate Professor, Department of Surgery, Section of Urology, Geisel School of Medicine at Dartmouth

Vernon M Pais, Jr, MD is a member of the following medical societies: Alpha Omega Alpha, American Urological Association, Endourological Society, Sigma Xi, The Scientific Research Honor Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: consultant -- Boston Scientific.

Coauthor(s)

Grace E Sollender, MD Resident Physician, Department of Urology, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Frank and Linda Vala Endowed Chair of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Division of Urology, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoscopic and Robotic Surgeons, Society of University Urologists

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Endourological Society Board of Directors<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cook Medical<br/>Received research grant from: Cook Medical.

Acknowledgements

Andrew A Aronson, MD, FACEP Vice President, Physician Practices, Bravo Health Advanced Care Center; Consulting Staff, Department of Emergency Medicine, Taylor Hospital

Andrew A Aronson, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, Massachusetts Medical Society, and Society of Hospital Medicine

Disclosure: Nothing to disclose.

Alex Jacocks, MD Program Director, Professor, Department of Surgery, University of Oklahoma School of Medicine

Disclosure: Nothing to disclose.

Richard Lavely, MD, JD, MS, MPH Lecturer in Health Policy and Administration, Department of Public Health, Yale University School of Medicine

Richard Lavely, MD, JD, MS, MPH is a member of the following medical societies: American College of Emergency Physicians, American College of Legal Medicine, and American Medical Association

Disclosure: Nothing to disclose.

Eric L Legome, MD Chief, Department of Emergency Medicine, Kings County Hospital Center; Associate Professor, Department of Emergency Medicine, New York Medical College

Eric L Legome, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Michael T Marynowski, DO Staff Physician, Department of Emergency Medicine/Internal Medicine, Allegheny General Hospital

Disclosure: Nothing to disclose.

David L Morris, MD, PhD, FRACS Professor, Department of Surgery, St George Hospital, University of New South Wales, Australia

David L Morris, MD, PhD, FRACS is a member of the following medical societies: British Society of Gastroenterology

Disclosure: RFA Medical None Director; MRC Biotec None Director

Erik D Schraga, MD Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Richard H Sinert, DO Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Todd Thomsen, MD Instructor in Medicine, Consulting Staff, Department of Emergency Medicine, Mount Auburn Hospital

Todd Thomsen, MD is a member of the following medical societies: American College of Emergency Physicians, Massachusetts Medical Society, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.